 A study analyzed the cost effectiveness of using quadrivalent influenza vaccine, QIV, vs. trivalent influenza vaccine, TIV, as a vaccination strategy in Taiwan, and found that QIV would bring an additional 10,557 quality adjusted life years at an extra cost of US$9.4 million, yielding an ICER of US, Bin, Shizirou 15 per QALY gained. The study used a lifetime multi-cohort, static mark-off model with nine age groups and direct costs obtained from a database released by the Ministry of Health and Welfare. Results showed that QIV could be considered as a cost-effective strategy within the context of public health in Taiwan. This article was authored by Ming Chenyang, Elise Kiyohui Tan, NGNG-SU.